Aethlon Medical Inc. reported its financial results for the third quarter (Q3) ended December 31, 2025. The company posted consolidated operating expenses of approximately 2.06 million ISO, reflecting a 13.6% increase, primarily due to higher payroll expenses. As of December 31, 2025, Aethlon Medical held a cash balance of about 7.0 million ISO. Total stockholders’ equity stood at 6.71 million ISO at the end of the period, while total liabilities and stockholders’ equity amounted to 8.06 million ISO. The accumulated deficit was 173.22 million ISO. Operationally, Aethlon Medical achieved a 26.9% reduction in operating expenses during the nine months ended December 31, 2025, as part of ongoing cost optimization efforts while advancing clinical and research programs. The company continues to focus on developing products targeting cancer and life-threatening infectious diseases, with CEO and CFO James Frakes highlighting recent progress in trials, research collaborations, and technology development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA86076) on February 12, 2026, and is solely responsible for the information contained therein.